The content on this site is intended for healthcare professionals only
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trast...
Prof Nadia Harbeck - University of Munich, Munich, Germany
18 Sep 2021
Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone recept...
Dr Mafalda Oliveira - Vall d'Hebron University Hospital, Barcelona, Spain
18 Sep 2021
OncoAlert and ecancer - ESMO 2021 Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
18 Sep 2021
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast ca...
Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom
17 Sep 2021
ESMO President: What to watch for at ESMO 2021
Prof Solange Peters - ESMO President
17 Sep 2021
OncoAlert and ecancer weekly round up for August 23rd - August 29th, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
31 Aug 2021
OncoAlert and ecancer weekly round up for August 2 - August 14, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
16 Aug 2021
OncoAlert and ecancer weekly round up for July 26 - August 1, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
2 Aug 2021
Targeted therapy for breast cancer
Dr Aurelio Castrellon - Memorial Healthcare System, Florida, USA
28 Jul 2021
Triple negative breast cancer: OlympiA study
Dr Zeina Nahleh - Cleveland Clinic Weston, Florida, USA
28 Jul 2021
OncoAlert and ecancer weekly round up for July 19 - July 25, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
26 Jul 2021
OncoAlert and ecancer weekly round up for July 12- July 18, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
19 Jul 2021
